Philip has more than 20 years' experience writing about companies, general finance and investing matters for a variety of publications. His career has involved spells at the Investors Chronicle, where he was small companies and companies editor, Investors Week and most recently as editor of online financial news wire Sharecast. He has also contributed to a wide range of financial-focused publications on a freelance basis.
Arix is trading at a discount even to the estimated half-year net asset value of 180p
Valirx raised just short of a £1mln in May to progress the clinical trial of VAL201 and to advance the pre-clinical programmes, VAL101 and VAL301.
In Canada, which legalised medicinal products in 2001, sales are predicted to soar to C$10bn (£5.8bn).
Midatech wants to demonstrate that Q-Octreotide can achieve safe and effective growth hormone levels while also highlighting the advantages of its release system
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"
The pharma saw a major revolt over its executive pay on Wednesday with more than 20% of shareholders voting against the board’s remuneration
Mediclinic’s bid for the outstanding 70% of Spire was rejected by the UK healthcare group
Venture Life already manufactures numerous products for Alliance and the agreement confirms the extension of these arrangements to 31 December 2025.
Redx said today it has £13.6mln in the bank, which should last it into early 2019
In a £1bn deal, won against five other tenders, Morrison's will supply Safeway products and other national brands to 1,300 McColl's stores and 350 newsagents
British Telecom is developing a habit for unpleasant surprises